View More Recent Stories

Apr 9, 2021 06:12AM Greenwich LifeSciences (GLSI) Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
Apr 9, 2021 05:00AM Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
Mar 23, 2021 06:00AM Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference
Mar 11, 2021 06:00AM Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
Mar 10, 2021 07:59PM Greenwich LifeSciences CEO to be Interviewed Live on Benzinga’s Power Hour
Mar 8, 2021 06:00AM Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
Mar 2, 2021 06:00AM Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences
Dec 11, 2020 06:36AM Greenwich LifeSciences (GLSI) Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer
Dec 11, 2020 06:00AM Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer
View More Recent Stories